In tumor supernatants, Sharma et al. demonstrated that DCs had reduced surface expression of major histocompatibility complex (MHC) class I and II and co-stimulatory molecules (e.g., CD80 and CD86) in vitro, reducing their capacity to present tumor-specific antigens for T-cell activation [40]. The gene discussed is CD80; the disease is neoplasm.